The present study aims to compare between two medications of migraine, ubrogepant and eletriptan (triptans), in terms of general characteristics, efficacy, and special considerations of use. Topics of discussion in the study include the following: overview of migraine, types of pharmacological treatments of migraine, overview of ubrogepant, considerations in the use of ubrogepant for treating migraine, overview of triptans, and considerations in the use of triptans for treating migraine. The study also involves conducting a descriptive study to compare the efficacy of the two medications on a sample of (56) patients at three large general hospitals located in the city of Jeddah, Saudi Arabia. Findings of the study do not show significant differences between the two medications in terms of efficacy and duration before feeling improvement, measured by extent of improvement. Sample members from both study groups also reported using similar additional medications. However, one significant aspect of difference between the two study groups concerns the reported side effects, although the incidence of such effects was rare in both groups. In the light of the findings, the researcher recommends conducing further research, on larger scale, to investigate, in more detail, the potential side effects of using ubrogepant or eletriptan in migraine treatment.

Keywords: Ubrogepant, Triptans, Eletriptan, Migraine.